APPLICATION OF ERBISOL® ULTRAPHARM FOR THE TREATMENT OF PATIENTS WITH PANCREATIC CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-1-2019-g.7098Keywords:
pancreas cancer, Erbisol® Ultrapharm, chemotherapy, effectiveness, toxicity.Abstract
Summary. Aim: to study the effectiveness of the use of
Erbisol® Ultrapharm in the complex treatment of patients with pancreatic cancer (PC). Object and methods: 88 patients with PC in the Т2–4N0–1М0–1.
36 patients with mechanical obstructive obstruction of
the biliary tract and duodenum have undergone surgical intervention according to indications. All patients received monochemotherapy with gemcitabine
(1000 mg/m2
, intravenously, 1-, 8-, 15-day, 4 courses
at 28-day intervals). Control group — 42 patients received only monochemotherapy; main group — 46 patients received chemotherapy (CT) and Erbisol® Ultrapharm (intramuscularly; 16 cycles of 7 days: 5 days —
2 times a day (4 ml in the morning, 2 ml in the evening),
2 days — 1 time (2 ml in the evening). Two months after CT completion, 2 courses of support and rehabilitation with Erbisol® Ultrapharm were conducted. The
standard clinical, laboratory and instrumental methods
of examination of patients were used. The observation
time was 1 year. The efficacy of Erbisol® Ultrapharm
was assessed by the levels of objective tumor response,
the duration of the period of disease stabilization and
survival of patients, the characteristics of their quality
of life, and the parameters of toxicity. Results: the inclusion of Erbisol® Ultrapharm in basіс therapy contributed to improve the parameters clinical symptoms, reduced the effects of CT, decreased the severity of subjective complaints, improved quality of life for patients
(Karnovsky-index in patients main group: 67.8% — before treatment and 70.0% — at the end of the investigation; in the control group — 67.9% and 60.0%, respectively). Partial regression of the primary tumor was
noted in 39.1% in the main group and in 19.1% in the
control group (p < 0.05). The duration of disease stabilization and overall survival were significantly higher in the main group compared with the control group
(p < 0.05). Conclusion: the use of the drug Erbisol® Ultrapharm allowed to increase the effectiveness of treatment and to reduce the toxicity of CT of patients with
PC stage T2–4N0–1M0–1.
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.
Cancer in Ukraine, 2016–2017. Incidence, mortality, activities of oncological service. Bull Natl Cancer Registry of Ukr, Kyiv 2018; 19: 136 p. (in Ukrainian).
Grinevich YuA. Immunotherapy in antitumor and antirecurrent treatment of cancer patients. Doctor 2003; 4: 32–4 (in Russian).
Diwanay S, Gautam M, Patwardhan B. Cytoprotection and immunomodulation in cancer therapy. Curr Med Chem Anticancer 2004; 4 (6): 479–90.
Pischikov OK. Efficiency of Glutargin and Erbisol combination in treatment of patients with laryngeal cancer. Problems
of Ecological and Medical Genetics and Clinical Immunology 2003; 6 (52): 206–12 (in Ukrainian).
Stepula VV, Kuznetsov OV, Martsinkovskaya NV. Use of Erbisol® on the background of the chemotherapy of patients with ovary cancer. Oncology 2004; 6 (3): 40 (in Russian).
Glavatskiy OYa, Danchuk SV, Khassan A, et al. Еrbisol® Ultrapharm in the treatment of patients with prolonged growth of glial tumors of the brain. Farmakologiya ta Likarska Toksykologiya 2010; 3 (16): 65–70 (in Ukrainian).
Maksimiak GI, Chyshkevich YuV, Smirnov GYu, et al. Clinical aspects of the use of Erbisol® medications in the complex therapy of solid tumors. Oncology 2010; 12 (3): 287–91 (in Russian).
Gladkiy AV. Use of Erbisol Ultrapharm in regional polychemotherapy of malignant tumors. Zb Naukovyh Prats KMAPO
; 14 (1): 202–8 (in Russian).
Nikolayenko AN. Pharmacological features of highly effective medications of new generation of «Erbisol» class. Praktikuyuchiy Likar 2010; 2 (7): 5–15 (in Russian).
Nikolayenko AN, Bazyka DA, Drannik GN, et al. Influence of Erbisol preparations on production of cytokines and expression
of surface markers of cell blood in healthy donors and oncological patients. Eurasian J Oncol 2016: 4 (1): 79–89 (in Russian).
Nikolayenko AN, Cheremshenko NL, Dibenko GV, et al. Antitumor activity of drugs of the class «Erbisol» in vitro i in vivo. Oncology 2011; 13 (4): 2–6 (in Russian).
Chubenko AV, Babich PN, Lapach SN, et al. Principles of application of statistical methods in conducting clinical trials of medicinal products: Methodical Recommendations. АVК Izdatel’skiy dom «Аvitsenna» 2003: 60 p. (in Russian).
